Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 09, 2018 06:15 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals to Present Posters on Varlitinib and ASLAN003 at European Society for Medical Oncology Congress

SINGAPORE, Oct. 09, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT, Nasdaq: ASLN), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia...
September 21, 2018 04:00 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Presents Two Posters on Varlitinib at Chinese Society of Clinical Oncology Annual Meeting

SINGAPORE, Sept. 21, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
September 17, 2018 06:58 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Provides Update on Timelines for Clinical Trial of Varlitinib in Biliary Tract Cancer in China

SINGAPORE, Sept. 17, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
September 04, 2018 02:47 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals to Present at HC Wainwright 20th Annual Global Investment Conference

SINGAPORE, Sept. 04, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
August 20, 2018 02:49 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Granted Orphan Drug Designation by the FDA for ASLAN003 for the Treatment of Acute Myeloid Leukaemia

SINGAPORE, Aug. 20, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
August 10, 2018 08:19 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Completes Recruitment for Global Phase 2 Study for Varlitinib in First Line Gastric Cancer

SINGAPORE, Aug. 10, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN) (TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
August 06, 2018 04:05 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update

SINGAPORE, Aug. 06, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
July 03, 2018 04:01 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Submits Clinical Trial Authorisation Application for First in Man Studies for ASLAN004

SINGAPORE, July 03, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT) (NASDAQ:ASLN), a clinical-stage biopharmaceutical company based in Asia developing novel therapeutics for global...
May 17, 2018 02:25 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals to Present Two Posters on Varlitinib at ASCO

SINGAPORE, May 17, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT) (Nasdaq:ASLN), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia...
May 04, 2018 10:59 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Prices Initial Public Offering of Its American Depositary Shares

SINGAPORE, May 04, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Limited (TPEx:6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...